First-line management of advanced non-small-cell lung cancer: can we do better?
作者信息
Chouaïd Christos, Monnet Isabelle, Auliac Jean-Bernard
机构信息
Service de Pneumologie, CHI Créteil, Créteil, France.
Inserm U955, UPEC, IMRB, Créteil, France.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1643-1648. doi: 10.21037/tlcr-23-200. Epub 2023 Jun 1.
Abstract
摘要
相似文献
1
First-line management of advanced non-small-cell lung cancer: can we do better?晚期非小细胞肺癌的一线管理：我们能否做得更好？
Transl Lung Cancer Res. 2023 Jul 31;12(7):1643-1648. doi: 10.21037/tlcr-23-200. Epub 2023 Jun 1.
2
Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis.免疫治疗联合化疗与单纯化疗作为 PD-L1 阴性和驱动基因阴性的晚期非鳞状非小细胞肺癌的一线治疗：一项更新的系统评价和荟萃分析。
Thorac Cancer. 2022 Nov;13(22):3124-3132. doi: 10.1111/1759-7714.14664. Epub 2022 Sep 26.
3
Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.信迪利单抗联合化疗用于晚期或转移性非鳞状非小细胞肺癌的一线治疗：网络荟萃分析。
Immunotherapy. 2023 Mar;15(4):293-309. doi: 10.2217/imt-2022-0252. Epub 2023 Feb 7.
4
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.免疫治疗单药与免疫治疗联合化疗作为晚期非小细胞肺癌一线治疗的间接比较：系统评价。
BMJ Open. 2020 Nov 20;10(11):e034010. doi: 10.1136/bmjopen-2019-034010.
5
Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review.早期非小细胞肺癌与晚期非小细胞肺癌免疫治疗疗效比较：系统评价。
BMC Med. 2022 Nov 7;20(1):426. doi: 10.1186/s12916-022-02580-1.
6
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).免疫疗法在任何治疗线均可改善晚期转移性非小细胞肺癌（NSCLC）患者的生存，优于化疗（Quijote-CLICaP）。
Thorac Cancer. 2020 Feb;11(2):353-361. doi: 10.1111/1759-7714.13272. Epub 2019 Dec 12.
7
Immunotherapy in Advanced Non-Small Cell Lung Cancer.晚期非小细胞肺癌的免疫治疗。
Semin Respir Crit Care Med. 2020 Jun;41(3):400-408. doi: 10.1055/s-0040-1710077. Epub 2020 May 25.
8
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.一位晚期肺鳞状细胞癌患者，在接受白蛋白结合紫杉醇联合帕博利珠单抗治疗后未获益，二线治疗采用多西他赛联合帕博利珠单抗后获得部分缓解：一例报告。
Ann Palliat Med. 2022 Sep;11(9):3020-3027. doi: 10.21037/apm-22-960.
9
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.一线免疫治疗联合化疗治疗广泛期小细胞肺癌患者的疗效和安全性：一项贝叶斯网络荟萃分析。
Front Immunol. 2023 Jun 26;14:1197044. doi: 10.3389/fimmu.2023.1197044. eCollection 2023.
10
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.中性粒细胞与淋巴细胞比值和 EPSILON 评分在一线化疗免疫治疗的晚期非小细胞肺癌患者中的预后作用。
Future Oncol. 2022 Jul;18(23):2593-2604. doi: 10.2217/fon-2021-1454. Epub 2022 Jun 20.
本文引用的文献
1
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.一线阿特珠单抗单药治疗与含铂方案治疗不适用的非小细胞肺癌患者的单药化疗（IPSOS）：一项全球、多中心、开放标签、随机对照的 3 期临床试验。
Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6.
2
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
3
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.纳武利尤单抗联合伊匹木单抗一线治疗转移性非小细胞肺癌，包括 ECOG 体能状态 2 分及其他特殊人群：CheckMate 817 研究
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006127.
4
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.度伐利尤单抗联合或不联合替西木单抗联合化疗作为转移性非小细胞肺癌一线治疗的 III 期 POSEIDON 研究。
J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.
5
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.海王星研究：度伐利尤单抗联合曲美木单抗一线治疗转移性非小细胞肺癌的3期研究。
J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12.
6
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.纳武利尤单抗联合伊匹单抗对比化疗作为一线治疗用于 CheckMate 227 研究转移性非小细胞肺癌的 5 年生存结果。
J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12.
7
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.西妥昔单抗联合化疗对比单纯化疗治疗非小细胞肺癌：一项随机、对照、双盲的 3 期临床试验。
Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25.
8
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).一线单药帕博利珠单抗治疗 PD-L1 阳性（肿瘤比例评分≥50%）的晚期非小细胞肺癌的真实世界研究：脑转移的影响：一项全国性的法国多中心队列研究（ESCKEYP GFPC 研究）。
Cancer Immunol Immunother. 2023 Jan;72(1):91-99. doi: 10.1007/s00262-022-03232-2. Epub 2022 Jun 21.
9
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.一线免疫检查点抑制剂单药治疗或联合化疗的非小细胞肺癌患者基线肿瘤大小与预后的关联
Transl Lung Cancer Res. 2022 Feb;11(2):135-149. doi: 10.21037/tlcr-21-815.
10
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.肿瘤负担与治疗初治晚期非小细胞肺癌的程序性细胞死亡受体 1/程序性细胞死亡配体 1 抑制剂疗效的关系。
Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15.
Zotero 插件